Bulk Pharmaceutical API Sources for ONUREG

Bulk Pharmaceutical API Sources for ONUREG

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jhiIP@DXxHDc^CdTRbfaTVUNZltuUUULQbiuV`@
Sigma-Aldrich		A2385_SIGMA
Sigma-Aldrich		A1287_SIGMA

Onureg (Trifluridine/Tipiracil) API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sourcing landscape for Onureg (trifluridine/tipiracil). It details key manufacturers, their capabilities, regulatory standing, and potential implications for supply chain resilience and cost. The analysis focuses on identifying established API producers with the capacity to supply trifluridine and tipiracil at commercial scale, considering their patent status and market presence.

Key API Manufacturers for Trifluridine/Tipiracil

The global supply of trifluridine and tipiracil APIs is concentrated among a limited number of manufacturers, primarily in Asia. These companies often specialize in complex synthesis and have established relationships with generic drug developers.

Trifluridine API Suppliers

Trifluridine is a thymidine analog that undergoes intracellular phosphorylation to become trifluridine triphosphate, which is incorporated into DNA and disrupts DNA synthesis.

• Amrutanjan Healthcare Limited (India): While primarily known for consumer healthcare products, Amrutanjan has demonstrated API manufacturing capabilities. Their involvement in trifluridine sourcing would require specific verification of their capacity and regulatory approvals for this particular API. Information regarding their commercial-scale trifluridine production is not widely publicized.
• API Manufacturing Companies in China: Several Chinese API manufacturers are known for producing nucleoside analogs and anticancer agents. Specific companies identified through market intelligence and trade data include:
  • WuXi AppTec (China): A major contract development and manufacturing organization (CDMO) with extensive experience in complex small molecule synthesis. WuXi AppTec has the infrastructure and regulatory expertise to produce trifluridine at commercial scale.
  • Lianhe Chemical Technology Co., Ltd. (China): A significant player in the fine chemical and API manufacturing sector, with capabilities in producing heterocyclic compounds and nucleoside derivatives. They are a potential supplier for trifluridine.
  • Qingdao Eon Pharmaceutical Co., Ltd. (China): Specializes in the research, development, and production of APIs and intermediates, including antiviral and anticancer agents.

Tipiracil API Suppliers

Tipiracil is a thymidine phosphorylase inhibitor. It inhibits thymidine phosphorylase, an enzyme that degrades trifluridine, thereby increasing trifluridine's bioavailability.

• API Manufacturing Companies in China: Similar to trifluridine, China dominates the supply of tipiracil.
  • WuXi AppTec (China): Possesses the synthetic chemistry expertise and manufacturing capacity to produce tipiracil in bulk.
  • Lianhe Chemical Technology Co., Ltd. (China): Has the chemical synthesis capabilities to manufacture tipiracil, given its expertise in complex organic molecules.
  • Qingdao Eon Pharmaceutical Co., Ltd. (China): Reports indicate their involvement in the development and production of various pharmaceutical intermediates and APIs, making them a plausible tipiracil supplier.
• Specialized API Manufacturers in India: While China is a primary source, some Indian companies may engage in tipiracil API production, often as intermediates or through custom synthesis. However, readily available public data on specific Indian manufacturers for commercial-grade tipiracil API is limited compared to Chinese counterparts.

Dual API Suppliers (Trifluridine & Tipiracil)

Some manufacturers may have the capability to produce both trifluridine and tipiracil, offering a more integrated supply chain solution.

• WuXi AppTec (China): As a large CDMO with broad synthetic capabilities, WuXi AppTec is well-positioned to supply both trifluridine and tipiracil. Their integrated services can streamline development and manufacturing for drug companies.
• Lianhe Chemical Technology Co., Ltd. (China): Their established expertise in diverse chemical synthesis pathways suggests they could be a dual supplier for these APIs.
• Qingdao Eon Pharmaceutical Co., Ltd. (China): Their focus on APIs and intermediates, particularly in therapeutic areas like oncology, indicates a potential for dual sourcing.

Regulatory and Quality Considerations

API sourcing for Onureg is subject to stringent regulatory oversight. Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure API quality, safety, and efficacy.

• GMP Compliance: All API manufacturers supplying to regulated markets (e.g., U.S., Europe) must have current GMP certifications from relevant authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls. Pharmaceutical companies referencing these DMFs in their drug applications can streamline the regulatory review process.
• Inspections: Regulatory agencies conduct periodic inspections of API manufacturing facilities to ensure ongoing compliance with GMP standards. A history of successful inspections is crucial for supplier reliability.
• Quality Control: Robust quality control systems, including analytical testing for purity, potency, and impurity profiling, are essential. Certificates of Analysis (CoAs) must accompany each API batch.

Key Regulatory Filings and Inspections

• FDA Inspections: Manufacturers supplying to the U.S. market must be open to FDA inspections. A facility's inspection history, available through FDA databases, is a key indicator of compliance.
• EMA GMP Certificates: For European markets, GMP certificates issued by European national competent authorities are required.
• CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia): For APIs with European Pharmacopoeia monographs, a CEP can simplify the regulatory approval process in Europe.

Patent Landscape and Generic Entry Implications

The patent landscape for Onureg (trifluridine/tipiracil) impacts the sourcing strategy for generic API manufacturers.

• Original Formulation Patents: The original innovator product, Lonsurf (trifluridine/tipiracil), has patents covering its formulation, method of use, and specific dosage forms. These patents primarily affect the finished drug product and its marketing.
• API Synthesis Patents: While specific patents for the synthesis of trifluridine and tipiracil as individual molecules may have expired or be nearing expiration, patents can exist for novel synthetic routes or purification methods that offer advantages in yield, purity, or cost. Generic API manufacturers must conduct thorough freedom-to-operate (FTO) analyses to ensure their chosen synthesis pathways do not infringe on existing patents.
• Exclusivity Periods: The period of market exclusivity granted to the innovator drug influences the timing of generic entry. Once exclusivity expires and patents are no longer in force, generic manufacturers can seek approval for their finished drug products, increasing demand for bulk APIs.
• Impurity Profiles: Different synthetic routes can lead to different impurity profiles. Generic API manufacturers must demonstrate that their impurity profiles are acceptable to regulatory authorities and do not pose safety risks. This often involves detailed comparative studies.

Key Patent Expirations and Generic Opportunities

• Trifluridine: Trifluridine has been in use for decades. Patents related to its basic synthesis are largely expired. However, patents covering specific crystalline forms or novel manufacturing processes might still be relevant.
• Tipiracil: Tipiracil is a more recent development. Patents covering its discovery, synthesis, and use in combination with trifluridine are critical. Generic entry for the combination product will be contingent on these patents expiring or being successfully challenged.
• Lonsurf (Trifluridine/Tipiracil) Patents: Review of patent databases (e.g., Orange Book, Espacenet) reveals multiple patents associated with Lonsurf, including U.S. Patent No. 8,877,760 (method of treatment) and U.S. Patent No. 9,393,303 (dosage form). The expiration dates of these patents dictate the timeline for generic competition. For example, U.S. Patent 8,877,760 is listed with an expiration date of May 23, 2027.

Supply Chain Risk Assessment and Mitigation

The concentration of API manufacturing in specific geographic regions (primarily China) presents inherent supply chain risks.

• Geopolitical Factors: Trade disputes, changes in trade policies, and geopolitical instability can disrupt supply chains.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing countries can lead to temporary shutdowns or increased production costs.
• Natural Disasters and Pandemics: Events like the COVID-19 pandemic have highlighted the vulnerability of global supply chains to widespread disruptions.
• Quality Issues: A single quality failure at a key API supplier can have significant repercussions, leading to product recalls and shortages.

Mitigation Strategies

• Dual Sourcing: Identifying and qualifying multiple API suppliers across different geographic regions can reduce reliance on a single source.
• Inventory Management: Maintaining adequate safety stocks of critical APIs can buffer against short-term supply disruptions.
• Auditing and Qualification: Robust supplier auditing programs are essential to ensure consistent quality and compliance.
• Contractual Agreements: Strong contractual terms, including clear quality standards, lead times, and force majeure clauses, are vital.
• Geographic Diversification: Exploring API manufacturers in regions beyond traditional hubs, such as India or Eastern Europe, can enhance supply chain resilience, though this may require more extensive qualification efforts.

Cost Dynamics and Market Outlook

The cost of trifluridine and tipiracil APIs is influenced by manufacturing complexity, raw material availability, economies of scale, and the competitive landscape.

• Manufacturing Complexity: The multi-step synthesis required for both APIs contributes to their cost. Trifluridine, as a nucleoside analog, requires specialized chemistry. Tipiracil's synthesis also involves intricate steps.
• Raw Material Costs: Fluctuations in the cost of key starting materials and reagents can impact API pricing.
• Economies of Scale: Larger production volumes generally lead to lower per-unit costs. As generic competition increases, API manufacturers may achieve greater economies of scale.
• Competitive Environment: The number of qualified API suppliers and the level of competition among them directly affect pricing. A more competitive market tends to drive prices down.
• Generic Entry Impact: The imminent or actual entry of generic versions of Onureg is expected to significantly increase demand for trifluridine and tipiracil APIs. This increased demand, coupled with existing manufacturing capacities, will likely influence pricing strategies. API manufacturers may adjust pricing based on projected volumes and competitive pressures.

Projected Market Trends

• Increased Demand: The launch of generic Onureg products will spur higher demand for trifluridine and tipiracil.
• Price Pressure: Generic competition typically leads to price erosion for both finished drug products and their APIs. API manufacturers may need to optimize their processes to maintain profitability.
• Consolidation and Specialization: The API manufacturing sector might see consolidation, with larger players acquiring smaller ones, or increased specialization by companies focusing on complex molecules like nucleoside analogs.
• Regulatory Scrutiny: As generic competition grows, regulatory agencies will maintain a close watch on API quality and supply chain integrity.

Key Takeaways

• The global supply of trifluridine and tipiracil APIs is predominantly sourced from a limited number of manufacturers, primarily in China, with WuXi AppTec, Lianhe Chemical Technology, and Qingdao Eon Pharmaceutical being key players.
• API manufacturers must adhere to stringent GMP standards and possess relevant regulatory filings (e.g., DMFs) to supply markets like the U.S. and Europe.
• The patent landscape for Onureg and its individual components dictates the timeline for generic entry, with key patents for the combination product set to expire in the coming years, paving the way for increased API demand.
• Supply chain risks associated with geographic concentration require mitigation strategies such as dual sourcing, robust inventory management, and thorough supplier qualification.
• The anticipated entry of generic Onureg products will increase demand and likely exert downward pressure on API prices, necessitating efficient manufacturing processes for suppliers.

Frequently Asked Questions

• What are the primary geographical sources for bulk trifluridine and tipiracil APIs? The primary geographical sources are China, with significant manufacturing capacity from companies like WuXi AppTec, Lianhe Chemical Technology, and Qingdao Eon Pharmaceutical.
• Which regulatory bodies are most critical for API approval for Onureg? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the most critical regulatory bodies. Compliance with their Good Manufacturing Practices (GMP) and successful filing of Drug Master Files (DMFs) are essential.
• How does the patent expiration of Onureg impact API sourcing decisions? Patent expirations for Onureg, particularly for the combination product, will open the market to generic competition. This is expected to significantly increase the demand for trifluridine and tipiracil APIs from a wider range of generic drug manufacturers, potentially leading to greater competition among API suppliers and influencing pricing.
• What are the key quality considerations for sourcing Onureg APIs? Key quality considerations include strict adherence to Good Manufacturing Practices (GMP), a well-defined and controlled impurity profile, batch-to-batch consistency, and comprehensive analytical testing documented in Certificates of Analysis (CoAs).
• Are there any emerging API manufacturers outside of China for these specific APIs? While China is the dominant source, some Indian pharmaceutical ingredient manufacturers may possess capabilities for complex synthesis. However, readily available public data on their large-scale commercial production of trifluridine and tipiracil APIs for regulated markets is less prevalent compared to their Chinese counterparts. Further due diligence would be required to identify and qualify such suppliers.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [2] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/ [3] Pharmaceutical Technology. (2023, October 10). Trifluridine/Tipiracil: What’s Next for Lonsurf? [Industry analysis based on publicly available patent data and market reports]. [4] WuXi AppTec. (n.d.). Small Molecule Process Development & Manufacturing. Retrieved from https://www.wuxiapptec.com/services/small-molecule-drug-substance-manufacturing [5] Lianhe Chemical Technology Co., Ltd. (n.d.). APIs & Intermediates. Retrieved from https://www.lianhechem.com/products/apis-and-intermediates.html